Histone-modifying genes as biomarkers in hepatocellular carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2496-2507

  Hung, Shih Ya ^a,b   Lin, Hui Hua ^a   Yeh, Kun Tu ^c   Chang, Jan Gowth ^a,b,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hepatocellular carcinoma; Histone acetylation; Histone methylation; Histone modification; Histone phosphorylation

Indexed keywords

EZH2 PROTEIN, HUMAN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; MESSENGER RNA; POLYCOMB REPRESSIVE COMPLEX 2; SUV39H2 PROTEIN, HUMAN; TUMOR MARKER;

BIOPSY; CANCER GRADING; CANCER STAGING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; METHYLATION; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PREDICTIVE VALUE; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TAIWAN; TIME; TISSUE MICROARRAY; UPREGULATION; VIROLOGY;

BIOPSY; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; METHYLATION; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PREDICTIVE VALUE OF TESTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TAIWAN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84902437660     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Maluccio M and Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62: 394-399.
4. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-78.
5. Song do S and Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol 2012; 18: 258-267.
6. Kornberg RD and Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999; 98: 285-294.
7. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-398.
8. Herceg Z and Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res 2011; 727: 55-61.
9. Dawson MA and Kouzarides T. Cancer epigenetics:from mechanism to therapy. Cell 2012; 150: 12-27.
10. Arrowsmith CH, Bountra C, Fish PV, Lee K and Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
11. Jones PA and Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
12. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447: 433-440.
13. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P, Fusco A and Portella G. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005; 90: 928-935.
14. Taby R and Issa JP. Cancer epigenetics. CA Cancer J Clin 2010; 60: 376-392.
15. Sharma S, Kelly TK and Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
16. Keen N and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-936.
17. Jeng YM, Peng SY, Lin CY and Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-2071.
18. Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, Lee PH, Cheng AL and Hsu HC. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 2010; 10: 461.
19. Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y and Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009; 50: 518-527.
20. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y and Allis CD. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 2003; 12: 1591-1598.
21. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H and Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002; 16: 1779-1791.
22. Simon JA and Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev 2002; 12: 210-218.
23. Cai MY, Tong ZT, Zheng F, Liao YJ, Wang Y, Rao HL, Chen YC, Wu QL, Liu YH, Guan XY, Lin MC, Zeng YX, Kung HF and Xie D. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011; 60: 967-976.
24. Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M and Jenuwein T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001; 107: 323-337.
25. Kondo Y, Shen L, Suzuki S, Kurokawa T, Masuko K, Tanaka Y, Kato H, Mizuno Y, Yokoe M, Sugauchi F, Hirashima N, Orito E, Osada H, Ueda R, Guo Y, Chen X, Issa JP and Sekido Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007; 37: 974-983.
26. Fan DN, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, Lee JM, He X, Ng IO and Wong CM. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology 2013; 57: 637-647.
27. Edge SB and Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.
28. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY and Chang CS. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003; 123: 654-661.
29. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
30. Lee CL, Ko YC and Choong CS. Survival rate for liver cancer in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63: 16-20.
31. Shyu HJ, Lung CC, Ho CC, Sun YH, Ko PC, Huang JY, Pan CC, Chiang YC, Chen SC and Liaw YP. Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: an ecological study. BMC Public Health 2013; 13: 352.
32. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY and Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859.
33. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
34. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
35. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M and Gilks CB. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002; 15: 1374-1380.
36. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G and Jones PA. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002; 62: 6456-6461.
37. Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y, Haddad BR and Issa JP. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One 2008; 3: e2037.
38. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118: 409-418.
39. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH and Issa JP. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-750.
40. Chen JH, Yeh KT, Yang YM, Chang JG, Lee HE and Hung SY. High expressions of histone methylation-and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan. Med Oncol 2013; 30: 513.
41. Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A and Konishi I. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium:Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 2005; 36: 1281-1288.
42. Keating GM and Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
43. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
44. Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H, Wakiyama S, Fujita H, Shirouzu K and Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92: 1754-1758.
45. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T and Nakanuma Y. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008; 88: 873-882.
46. Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A and Yokosuka O. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 2009; 40: 1304-1311.
47. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J and Kung HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-208.
48. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH, Chien MH, Yang CJ, Huang MS, Hsiao M and Kuo ML. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010; 70: 7830-7840.